ROCKVILLE, Md., Aug. 30 /PRNewswire-FirstCall/ — Stem cell company, Neuralstem, Inc. (Amex: CUR – News), today announced it has entered into a collaborative agreement with the ALS Clinic at University of Michigan Health System, directed by Eva Feldman, M.D., Ph.D., the De Jong Professor of Neurology at the U-M Medical School. The goal of the collaboration is to provide further proof-of-principle data to move Neuralstem’s spinal cord stem cells into patients with Amyotrophic Lateral Sclerosis (ALS), or Lou Gehrig’s disease. ALS is a motor neuron disease, which strikes people between the ages of 40 and 70. As many as 30,000 Americans have the disease at any given time. Read the full article here.